Showing 1 - 20 results of 35 for search '"ТРАНСПЛАНТАЦИЯ СТВОЛОВЫХ КЛЕТОК"', query time: 0.68s Refine Results
  1. 1
  2. 2
    Academic Journal

    Source: Сборник статей

    File Description: application/pdf

    Relation: Актуальные вопросы современной медицинской науки и здравоохранения: материалы VII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 17-18 мая 2022 г.; http://elib.usma.ru/handle/usma/7915

  3. 3
    Academic Journal

    Contributors: Работа выполнена при поддержке Министерства здравоохранения Российской Федерации по программе НИОКРТ, № АААА-А18-118082290065-4.

    Source: Russian Journal of Transplantology and Artificial Organs; Том 23, № 1 (2021); 171-177 ; Вестник трансплантологии и искусственных органов; Том 23, № 1 (2021); 171-177 ; 1995-1191

    File Description: application/pdf

    Relation: https://journal.transpl.ru/vtio/article/view/1328/1097; https://journal.transpl.ru/vtio/article/view/1328/1196; www.who.int [Internet]. World Health Organization. Prevention of Blindness and Visual Impairment. Доступно по ссылке: http://www.who.int/blindness/causes/priority/en/index8.html от 26/02-2019 г.; Avadhanam VS, Liu CS. A brief review of Boston type-1 and osteo-odontokeratoprostheses. Br J Ophthalmol. 2015; 99: 878-887. doi:10.1136/bjophthalmol-2014-305359.; Либман ЕС, Калеева ЭВ, Рязанов ДП. Комплексная характеристика инвалидности вследствие офтальмопатологии в Российской Федерации. Российская офтальмология. 2012; 5: 24-26.; Dua HS, Azuara-Blanco A. Limbal Stem Cells of the Corneal Epithelium. Surv Ophthalmol. 2000; 44: 415425. PMID: 10734241.; Dua HS, Saini JS, Azuara-Blanco A, Gupta P. Limbal stem cell deficiency: concept, etiology, clinical presentation, diagnosis and management. Indian J Ophthalmol. 2000; 48: 83-92. PMID: 11116520.; Lim P, Fuchsluge TA, Jurkunas UV. Limbal stem celldeficiency and corneal neovascularization. Semin Ophthalmol. 2009; 24: 139-148. doi:10.1080/08820530902801478.; Roshandel D, Eslani M, Baradaran-Rafii A, Cheung AY, Kurji K, Jabbehdari S et al. Current and emerging therapies for corneal neovascularization. Ocul Surf. 2018; 16: 398-414. doi:10.1016/j.jtos.2018.06.004.; Friedenwald JS. Growth pressure and metaplasia of conjunctival and corneal epithelium. Doc Ophthalmol. 1951; 5-6: 184-192. PMID: 14896877.; Vazirani J, Mariappan I, Ramamurthy S, Fatima S, Basu S, Sangwan VS. Surgical Management of Bilateral Limbal Stem Cell Deficiency. Ocul Surf. 2016; 14: 350-364. doi:10.1016/j.jtos.2016.02.00.; Holland EJ. Management of Limbal Stem Cell Deficiency: A Historical Perspective, Past, Present, and Future. Cornea. 2015; 34: 9-15. doi:10.1097/ICO.0000000000000534.; Tsai RJ, Tseng SC. Human allograft limbal transplantation for corneal surface reconstruction. Cornea. 1994; 13: 389-400. PMID: 7995060.; Tsubota K, Toda I, Saito H, Shinozaki N, Shimazaki J. Reconstruction of the corneal epithelium by limbal allograft transplantation for severe ocular surface disorders. Ophthalmology. 1995; 102: 1486-1496. PMID: 9097796.; Holland EJ, Mogilishetty G, Skeens HM, Hair DB, Neff KD, Biber JM et al. Systemic immunosuppression in ocular surface stem cell transplantation: results of a 10-year experience. Cornea. 2012; 31: 655-661. doi:10.1097/ICO.0b013e31823f8b0c.; Utheim TP. Concise review: transplantation of cultured oral mucosal epithelial cells for treating limbal stem cell deficiency-current status and future perspectives. Stem Cells. 2015; 33: 1685-1695. doi:10.1002/stem.1999.; Inatomi T, Nakamura T, Koizumi N, Sotozono C, Yokoi N, Kinoshita S. Midterm results on ocular surface reconstruction using cultivated autologous oral mucosal epithelial transplantation. Am J Ophthalmol. 2006; 141: 267-275. doi:10.1016/j.ajo.2005.09.003.; Nishida K, Yamato M, Hayashida Y, Watanabe K, Yamamoto K, Adachi E et al. Corneal reconstruction with tissue engineered cell sheets composed of autologous oral mucosal epithelium. New Engl J Med. 2004; 351: 11871196. doi:10.1056/NEJMoa040455.; Nakamura T, Inatomi T, Sotozono C, Amemiya T, Kanamura N, Kinoshita S. Transplantation of cultivated autologous oral mucosal epithelial cells in patients with severe ocular surface disorders. Br J Ophthalmol. 2004; 88: 1280-1284. doi:10.1136/bjo.2003.038497.; Squier С., Brogden KA. Human Oral Mucosa: Development, Structure, and Function. John Wiley & Sons, Inc., 2011. - P. 23.; Satake Y, Higa K, Tsubota K, Shimazaki J. Long-term outcome of cultivated oral mucosal epithelial sheet transplantation in treatment of total limbal stem cell deficiency. Ophthalmology. 2011; 118: 1524-1530. doi:10.1016/j.ophtha.2011.01.039.; Baradaran-Rafii A, Delfazayebaher S, Aghdami N, Taghiabadi E, Bamdad S, Roshandel D. Midterm outcomes of penetrating keratoplasty after cultivated oral mucosal epithelial transplantation in chemical burn. Ocul Surf. 2017; 15: 789-794. doi:10.1016/j.jtos.2017.08.006.; Быков ВЛ. Гистология и эмбриональное развитие органов полости рта человека. М.: ГЭОТАР-Медиа, 2014: 391-393.; Squier С, Brogden KA. Human Oral Mucosa: Development, Structure, and Function. John Wiley & Sons, Inc.; 2011, 23.; Eroschenko VP. Di Fiore's atlas of histology with functional correlations. - 11th ed. - Lippincott Williams & Wilkins; 2005: 235-261.; Афанасьева ЮИ, Юрина НА. Гистология. М.: Медицина, 2002. 146.; Food and Drug Administration, HHS. Current good tissue practice for human cell, tissue, and cellular and tissue-based product establishments; inspection and enforcement. Final rule. Fed Regist. 2004; 69: 6861168688. PMID: 15562555.; Takagi R, Yamato M, Murakami D, Kondo M, Yang J, Ohki T et al. Preparation of keratinocyte culture medium for the clinical applications of regenerative medicine. J Tissue Eng Regen Med. 2011; 5: 63-73. doi:10.1002/term.337.; Ang LP, Nakamura T, Inatomi T, Sotozono C, Koizumi N, Yokoi N, et al. Autologous serum derived cultivated oral epithelial transplants for severe ocular surface disease. Arch Ophthalmol. 2006; 124: 1543-1551. doi:10.1001/archopht.124.11.1543.; Nakamura T, Takeda K, Inatomi T, Sotozono C, Kinoshita S. Long-term results of autologous cultivated oral mucosal epithelial transplantation in the scar phase of severe ocular surface disorders. Br J Ophthalmol. 2011; 95: 942-946. doi:10.1136/bjo.2010.188714.; Фрешни РЯ. Культура животных клеток. Практическое руководство. М.: Бином 2011. 427.; Boyce ST, Ham RG. Calcium-regulated differentiation of normal human epidermal keratinocytes in chemically defined clonal culture and serum-free serial culture. J Invest Dermatol. 1983; 81 (1 Suppl): 33s-40s. doi:10.1111/1523-1747.ep12540422.; Utheim TP, Utheim OA, Khan QE, Sehic A. Culture of Oral Mucosal Epithelial Cells for the Purpose of Treating Limbal Stem Cell Deficiency. J Funct Biomater. 2016; 7: 123. doi:10.3390/jfb7010005.; Murakami D, Yamato M, Nishida K, Ohki T, Takagi R, Yang J et al. Fabrication of transplantable human oral mucosal epithelial cells-sheets using temperature-responsive culture inserts without feeder layer cells. J Artif Organs. 2006; 9: 185-191. doi:10.1007/s10047-006-0342-3.; Nakamura T, Endo K, Kinoshita S. Identification of human oral keratinocytes stem/progenitor cells by neuro-trophin receptor p75 and the role of neurotrophin/p75 signaling. Stem cells. 2007; 25: 628-638. doi:10.1634/stemcells.2006-0494.; Wang JS, Xie HT, Zhang MC. Characterization of ex vivo Expanded Oral Mucosal Epithelium Cells on Acellular Porcine Corneal Stroma for Ocular Surface Reconstruction. J Ophthalmol. 2017; 67: 614-617. doi:10.1155/2017/676171.; Calenic B, Ishkitiev N, Yaegaki K, Imai T, Costache M, Tovaru M et al. Characterization of oral keratinocyte stem cells and prospects of its differentiation to oral epithelial equivalents. Rom J Morphol Embryol. 2010; 51: 641-645. PMID: 21103620.; Santibanez N. Immuno expression of E-cadherin and Vimentin in Normal Oral Mucosa, Oral Epithelial Displasiaand Oral Squamous Cell Carcinoma. Int J Morphol. 2017; 35: 596-602. PMID: 26045832.; Kasai Y, Sugiyama H, Takagi R, Kondo M, Owaki T, Namiki H et al. Brush biopsy of human oral mucosal epithelial cells as a quality control of the cell source for fabrication of transplantable epithelial cell sheets for regenerative medicine. Regenerative Therapy. 2016; 4: 71-77. doi:10.1016/j.reth.2016.02.008.; Nanda KDS, Ranganathan K, Devi U, Joshua E. Increased expression of CK8 and CK18 in leukoplakia, oral submucous fbrosis, and oral squamous cell carcinoma: an immunohistochemistry study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012; 113: 245-253. doi:10.1016/j.tripleo.2011.05.034.; Haagdorens M, Van Acker SI, Van Gerwen V, N Dhubhghaill S, Koppen C, Tassignon MJ et al. Limbal Stem Cell Deficiency: Current Treatment Options and Emerging Therapies. Stem Cells Int. 2016; 2016: 9798374. doi:10.1155/2016/9798374.; Ma DH, Kuo MT, Tsai YJ, Chen HC, Chen XL, Wang SF et al. Transplantation of cultivated oral mucosal epithelial cells for severe corneal burn. Eye. 2009; 23: 14421450. doi:10.1038/eye.2009.60.; Hirayama M, Satake Y, Higa K, Yamaguchi T, Shimazaki J. Transplantation of cultivated oral mucosal epithelium prepared in fibrin-coated culture dishes. IOVS. 2012; 53: 1602-1609. doi:10.1167/iovs.11-7847.; Tang Z, Okano T. Recent development of temperature-responsive surfaces and their application for cell sheet engineering. Regenerative Biomaterials. 2014; 1: 91102. doi:10.1093/rb/rbu011.; https://journal.transpl.ru/vtio/article/view/1328

  4. 4
    Academic Journal

    Source: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 9, No 1 (2016); 3-14 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 9, No 1 (2016); 3-14 ; 2070-4933 ; 2070-4909 ; 10.17749/2070-4909.2016.9.1

    File Description: application/pdf

    Relation: https://www.pharmacoeconomics.ru/jour/article/view/131/113; Зеленова О.В. Современные методы исследования порога готовности платить в сфере здравоохранения. Менеджер здравоохранения. 2011; 6. Режим доступа: http://cyberleninka.ru/article/n/sovremennye-metody-issledovaniya-poroga-gotovnosti-platit-v-sferezdravoohraneniya. Дата обращения: 16.10.2015.; Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. МНИОИ им. П.А. Герцена – филиал ФГБУ «ФМИЦ им. П.А. Герцена» Минздрава России. 2015; 250 с.; Основные производные показатели динамики обменного курса рубля в январе-ноябре 2015 года, ЦБ РФ. Режим доступа: http://www.cbr.ru/statistics/print.aspx?file=credit_statistics/ex_rate_ind_15. htm&pid=svs&sid=analit. Дата обращения: 16.10.2015.; О производстве и использовании валового внутреннего продукта (ВВП) за 2014 г., Росстат 2015 г. Режим доступа: http://www.gks.ru/bgd/free/b04_03/Isswww.exe/Stg/d05/18vvp2.htm. Дата обращения: 16.10.2015.; Постановление Правительства Российской Федерации от 28 ноября 2014 г. N 1273 «О программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2015 год и на плановый период 2016 и 2017 годов».; Распоряжение Правительства РФ от 26 декабря 2015 г. № 2724-р «Об утверждении перечня жизненно необходимых и важнейших лекарственных препаратов на 2016 год, а также перечней лекарственных препаратов для медицинского применения и минимального ассортимента лекарственных препаратов, необходимых для оказания медицинской помощи». Режим доступа: http://www.consultant.ru/document/cons_doc_LAW_192036/. Дата обращения: 16.10.2015.; Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под руководством проф. И.В. Поддубной, проф. В.Г. Савченко. М. 2014; 128 с.; Тарифное соглашение на оплату медицинской помощи, оказываемой по территориальной программе обязательного медицинского страхования города Москвы на 2015 год от 25 декабря 2014 г. Режим доступа: http://www.mgfoms.ru/system/files/tarifnoe_soglashenie_territorialnoy_oms_2015_god.pdf. Дата обращения: 16.10.2015.; Тарифы на медицинские услуги Московского городского реестра медицинских услуг в системе ОМС Тарифы на медицинские услуги, введенные в действие с 01.10.2014. Режим доступа: http://www.mgfoms.ru/system/files/fokt1014.xls. Дата обращения: 16.10.2015.; Численность населения Российской Федерации по муниципальным образованиям в 2014 г. Росстат 2015 г. Режим доступа: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/publications/catalog/afc8ea004d56a39ab251f2bafc3a6fce. Дата обращения: 16.10.2015.; Arai S., Fanale M., DeVos S. et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013 Nov; 54 (11): 2531-3. DOI:10.3109/10428194.2013.798868. Epub 2013 Jun 5.; De Bono J.S., Oudard S., Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2; 376 (9747): 1147-54. DOI:10.1016/S0140-6736(10)61389-X.; Diehl V., Sieber M., Ruffer U. et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin disease. The German Hodgkin Lymphoma Study Group. Ann Oncol. 1997; (2): 143-8.; Eichenauer D.A., Engert A., André M. et al. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol. 2014 Sep; 25 Suppl 3: iii70-5. DOI:10.1093/annonc/mdu181. Epub 2014 Jul 25.; El Gnaoui T., Dupuis J., Belhadj K. et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007; (8): 1363-8.; Gopal A.K., Chen R., Smith S.E. et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015 Feb 19; 125 (8): 1236-43. DOI:10.1182/blood-2014-08-595801. Epub 2014 Dec 22.; Gopal A., Chen R., Smith S. et al. Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma. American Society of Hematology Meeting 2013, abstract №4382. Режим доступа: https://ash.confex.com/ash/2013/webprogram/Paper57589.html. Дата обращения: 16.10.2015.; Heider A., Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin lymphomas. Anticancer Drugs. 2001; 9: 725-9.; Hoppe R.T., Advani R.H., Ai W.Z. et al. Hodgkin lymphoma, version 2.2015. J Natl Compr Canc Netw. 2015 May; 13 (5): 554-86.; Josting A., Rudolph C., Reiser M. et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin disease. Ann Oncol. 2002; 10: 1628-35.; Kaufman P.A., Awada A., Twelves C. et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015 Feb 20; 33 (6): 594-601. DOI:10.1200/JCO.2013.52.4892. Epub 2015 Jan 20.; Martinez C., Canals C., Alessandrino E.P. et al. Relapse of Hodgkin’s lymphoma after autologous stem cell transplantation (ASCT): identification of prognostic factors predicting outcome. Presentation at the 8th International Symposium on Hodgkin Lymphoma (ISHL), Cologne, October 26th.; Martinez C., Canals C., Sarina B. et al. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol. 2013 Sep; 24 (9): 2430-4. DOI:10.1093/annonc/mdt206. Epub 2013 May 26.; Ng M., Waters J., Cunningham D. et al. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer. 2005 (8): 1352-7.; Price T.J., Peeters M., Kim T.W. et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014 May; 15 (6): 569-79. DOI:10.1016/S1470-2045(14)70118-4. Epub 2014 Apr 14.; Radford J., McKay P., Peggs K. et al. Treatment pathways and resource use associated with the management of recurrent Hodgkin lymphoma after autologous stem cell transplantation. Presented at the 9th International Symposium on Hodgkin Lymphoma (ISHL), Cologne, Germany, October 2013.; Rini B.I., Halabi S., Rosenberg J.E. et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010 May 1; 28 (13): 2137-43. DOI:10.1200/JCO.2009.26.5561. Epub 2010 Apr 5.; Robinson S.P., Sureda A., Canals C. et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009 Feb; 94 (2): 230-8. DOI:10.3324/haematol.13441. Epub 2008 Dec 9.; Sarina B., Castagna L., Farina L. et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010; 115 (18): 3671-7.; Selby P., Patel P., Milan S. et al. ChlVPP combination chemotherapy for Hodgkin disease: long-term results. Br J Cancer. 1990; 2: 279-85.; Swinburn et al. Health state utilities for relapsed/refractory Hodgkin lymphoma (HL) and systemic anaplastic large-cell lymphoma (sALCL). Poster presented at the 17th Congress of the European Hematology Association (EHA). 2012 June 14-17; Amsterdam.; Younes A., Gopal A.K., Smith S.E. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012 Jun 20; 30 (18): 2183-9. DOI:10.1200/JCO.2011.38.0410. Epub 2012 Mar 26.; https://www.pharmacoeconomics.ru/jour/article/view/131

  5. 5
  6. 6
  7. 7
    Academic Journal

    Source: Modern Rheumatology Journal; Том 10, № 4 (2016); 87-91 ; Современная ревматология; Том 10, № 4 (2016); 87-91 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2016-4

    File Description: application/pdf

    Relation: https://mrj.ima-press.net/mrj/article/view/724/703; Эрдес ШФ, Бадокин ВВ, Бочкова АГ и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015;53(6):657-60 [Erdes ShF, Badokin VV, Bochkova AG, et al. On the terminology of spondyloarthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(6):657-60 (In Russ.)]. doi:10.14412/1995-4484-2015-657-660.; Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73:6-16. doi:10.1136/annrheumdis-2013-203419.; Гайдукова ИЗ, Ребров АП, Шувалова АА. Ремиссия при анкилозирующем спондилите и аксиальных спондилоартритах: современное понимание проблемы. Современная ревматология. 2016;10(1):48-51 [Gaydukova IZ, Rebrov AP, Shuvalova AA. Remission in ankylosing spondylitis and axial spondyloarthritis: A modern understanding of the problem. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(1): 48-51 (In Russ.)]. doi:10.14412/1996-7012-2016-1-48-51.; Sieper J, Lenaerts J, Wollenhaupt J, et al. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis. 2014 Jan;73(1):108-13. doi:10.1136/annrheumdis-2013-203460.; Kiltz U, Heldmann F, Baraliakos X, Braun J. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives? Curr Opin Rheumatol. 2012 May;24(3):252-60. doi:10.1097/BOR.0b013e3283524b82.; Rosa SB, Voltarelli JC, Chies JA, et al. The use of stem cells for the treatment of autoimmune diseases. Brazil J Med Biol Res. 2007;40:1579-97. doi:10.1590/S0100-879X2006005000166.; Hough RE, Snowden JA, Wulffraat NM. Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective. Br J Haematol. 2005 Feb;128(4):432-59. doi:10.1111/j.1365-2141.2004.05298.x.; Pasquini MC, Griffith LM, Arnold DL, et al. Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biol Blood Marrow Transplant. 2010 Aug;16(8):1076-83. doi:10.1016/j.bbmt.2010.03.012.; Snowden JA, Passweg J, Moore JJ, et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol. 2004 Mar;31(3):482-8.; Wulffraat M, de Kleer I, Brinkman D, et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: current results and perspectives. Transplant Proc. 2002 Nov;34(7):2925-6. doi:10.1016/S0041-1345(02)03490-5; Sui W, Hou X, Che W, et al. Hematopoietic and mesenchymal stem cell transplantation for severe and refractory systemic lupus erythematosus. Clin Immunol. 2013 Aug;148(2):186-97. doi:10.1016/j.clim.2013.05.014.; Jantunen E, Myllykangas-Luosujä rvi R, Kaipiainen-Seppä nen O, et al. Autologous stem cell transplantation in a lymphoma patient with a long history of ankylosing spondylitis. Rheumatology (Oxford). 2000; 39(5):563-4. doi:10.1093/rheumatology/39.5.563; Britanova OV, Bochkova AG, Staroverov DB, et al. First autologous hematopoietic SCT for ankylosing spondylitis: a case report and clues to understanding the therapy. Bone Marrow Transplant. 2012 Nov;47(11):1479-81. doi:10.1038/bmt.2012.44.; Wang P, Li Y, Huang L, et al. Effects and safety of allogenic mesenchymal stem cell intravenous infusion in active ankylosing spondylitis patients who failed NSAIDs: a 20-week clinical trial. Cell Transplant. 2014; 23(10):1293-303. doi:10.3727/096368913X667727.; Yang HK, Moon SJ, Shin JH, et al. Regression of syndesmophyte after bone marrow transplantation for acute myeloid leukemia in a patient with ankylosing spondylitis: a case report. J Med Case Rep. 2012 Aug 21;6:250. doi:10.1186/1752-1947-6-250.; Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994 Dec;21(12):2286-91.; Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994 Dec;21(12):2281-5.; Koch B, Kranzhö fer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000 Sep;26(6):673-5. doi:10.1038/sj.bmt.1702565.; Sari I, öztü rk MA, Akkoc N. Treatment of ankylosing spondylitis. Turk J Med Sci. 2015;45(2):416-30. doi:10.3906/sag-1401-79.; McGonagle D, Khan MA, MazzoOrtega H. Enthesitis in spondyloarthropathy. Curr Opin Rheumatol. 1999;11:244-50. doi:10.1097/00002281-199907000-00004.; Годзенко АА. Нестероидные противовоспалительные препараты: основа лечения анкилозирующего спондилита. Современная ревматология. 2011;5(4):66-8 [Godzenko AA. Nonsteroidal anti-inflammatory drugs: a basis for the treatment of ankylosing spondylitis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2011;5(4):66-68. (In Russ.)]. doi:10.14412/1996-7012-2011-702.; Marzo-Ortega H, O’Connor P, Emery P, et al. Sacroiliac joint biopsies in early sacroiliitis. Rheumatology (Oxford). 2007 Jul;46(7):1210-1. doi:10.1093/rheumatology/kem098.; Appel H, Kuhne M, Spiekermann S, et al. Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum. 2006 Jun;54(6):1805-13. doi:10.1002/art.21907.; Francois RJ, Neure L, Sieper J, et al. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis. 2006 Jun;65(6):713-20. doi:10.1136/ard.2005.037465.; Mamedov IZ, Britanova OV, Chkalina AV, et al. Individual characterization of stably expanded T cell clones in ankylosing spondylitis patients. Autoimmunity. 2009 Sep;42(6):525-36. doi:10.1080/08916930902960362.; Afessa B, Peters SG. Major complications following hematopoietic stem cell transplantation. Semin Respir Crit Care Med. 2006 Jun; 27(3):297-309. doi:10.1055/s-2006-945530.; Ikehara S. Bone marrow transplantation: a new strategy for intractable diseases. Drugs Today (Barc). 2002 Feb;38(2):103-11. doi:10.1358/dot.2002.38.2.820106.; Mamedov IZ, Britanova OV, Bolotin DA, et al. Quantitative tracking of T cell clones after haematopoietic stem cell transplantation. EMBO Mol Med. 2011 Apr;3(4):201-7. doi:10.1002/emmm.201100129.; Ананьева ЛП, Алекперов РТ, Насонов ЕЛ. Мезенхимальные клетки костного мозга – перспективы использования при ревматических болезнях. Научнопрактическая ревматология. 2013;51(1):59-67 [Ananyeva LP, Alekperov RT, Nasonov EL. Bone marrow mesenchymal cells: Promises for use in rheumatic diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(1):59-67 (In Russ.)]. doi:10.14412/1995-4484-2013-1203.; Karia VR, Cuchacovich R, Espinoza LR. Undifferentiated spondyloarthritis following allogeneic stem cell transplantation. BMC Musculoskelet Disord. 2010 Jun 25;11:132. doi:10.1186/1471-2474-11-132.

  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20